RVTY vs TMO: Which Is the Better Buy in 2026?
Last updated November 2026
Short answer
TMO is the larger of the two ($249.73B market cap): the incumbent the market prices for continued execution (24.26x forward earnings, beta 0.85). RVTY is the smaller challenger ($16.28B), priced similarly on forward earnings (24.48x): more room to run, but more to prove. If the story you believe is RVTY's (Diagnostics is carrying the growth, and newborn screening is carrying Diagnostics), RVTY is the more direct way to own it; if it is TMO's (Bioprocessing and Biologic Drug Manufacturing Tailwind), TMO is.
RVTY vs TMO: the tie-breaker metrics
Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | RVTY | TMO | What it tells you |
|---|---|---|---|
| Market cap | $16.28B | $249.73B | Size. The larger name is the incumbent; the smaller has more room to grow and more to prove. |
| Forward P/E | 24.48 | 24.26 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Trailing P/E | 64.80 | 35.55 | Valuation on the last 12 months. A big drop from trailing to forward means the market expects earnings to jump, so more growth is already in the price. |
| Beta | 1.09 | 0.85 | Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through. |
| Price vs 52-week range | 71% of range | 82% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
| Price / book | 2.24 | 4.56 | How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price. |
Before you buy: how RVTY and TMO affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. RVTY and TMO share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined RVTY and TMO exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does Revvity (RVTY) do?
Revvity runs two reporting segments of nearly identical size. Life Sciences sold ~$720.5 million in the first half of fiscal 2026 and covers two product lines: Life Sciences Solutions (~$601.0 million), meaning reagents, assays, labeling and detection chemistry, automation and high-content imaging systems such as the Opera Phenix platform, and Signals software (~$119.5 million), a scientific informatics suite sold on subscription to pharmaceutical R&D organizations. Diagnostics sold ~$720.3 million over the same period and also splits two ways: immunodiagnostics (~$416.6 million), largely the EUROIMMUN autoimmune, allergy and infectious-disease immunoassay franchise, and reproductive health (~$303.7 million), which is newborn screening, prenatal testing and related genomic services. Customers are pharmaceutical and biotech R&D groups, clinical and public-health laboratories, academia and governments across more than 160 countries, served by roughly 11,000 employees. Geography is spread wide rather than concentrated: in the June quarter the Americas produced ~$325.6 million, Europe ~$229.0 million and Asia ~$175.1 million. A large share of revenue is consumable or subscription in nature, since assays, reagents and screening kits get bought again every period, while instruments and software licenses carry the cyclical part of the business.
What does Thermo Fisher Scientific (TMO) do?
Thermo Fisher Scientific, headquartered in Waltham, Massachusetts, is a global provider of scientific instruments, consumables, reagents, and services used across pharmaceutical and biotech drug development, clinical diagnostics, academic research, and environmental and industrial testing. The company operates through four reportable segments: Life Sciences Solutions (reagents, proteins, and consumables for research and bioproduction), Analytical Instruments (mass spectrometers, chromatography systems, electron microscopes, and laboratory equipment), Specialty Diagnostics (clinical diagnostic kits and transplant diagnostics), and Laboratory Products and Biopharma Services (supply-chain distribution, contract research through PPD, and contract drug manufacturing through Patheon). Revenue is generated through instrument sales, high-margin consumables and reagents that customers repurchase continuously, long-term service contracts, and growing contract development and manufacturing (CDMO) fees; consumables and services collectively account for a majority of annual sales and provide durable recurring revenue.
RVTY vs TMO: how do they differ?
Both fit overlapping themes, but they are not interchangeable. Here is what each one depends on.
- RVTY drivers: Diagnostics is carrying the growth, and newborn screening is carrying Diagnostics; The China immunodiagnostics exit resets the base.
- TMO drivers: Bioprocessing and Biologic Drug Manufacturing Tailwind; Recurring Consumables and Reagents Engine.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: The most immediate risk is that a chunk of 2026 profit does not repeat. For TMO, the most significant near-term risk is a contraction in research funding from government agencies (including NIH) and from biotech companies whose access to capital markets has historically been cyclical; when funding tightens, customers delay instrument purchases and reduce consumable orders, pressuring organic revenue growth.
RVTY or TMO: which should you pick?
With growth, valuation and volatility this close (or not yet reported for one side), the drivers above are what separate RVTY from TMO. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the RVTY and TMO guides.
RVTY vs TMO: the full fundamentals
RVTY. The multiple depends entirely on which earnings line an owner treats as economic. A trailing GAAP P/E near 65x reflects ~$340 million a year of amortization on intangibles Revvity paid cash for in prior years; a multiple near 27x on 2026 consensus adjusted EPS, or about 24x on 2027 consensus, treats that amortization as sunk. After a roughly 48% gain in 2026 the stock carries a premium closer to faster-compounding life-science tools names than to slow-growth diagnostics, while reported revenue grew only about 4.3% in the third quarter. The fourth-quarter report, expected around February 1, 2027, is the next test of whether margin, buybacks and the instrument backlog can carry that premium.
TMO. Thermo Fisher trades at roughly 24 times forward earnings and ~36 times trailing GAAP earnings, which include heavy acquisition amortization, after a third quarter that beat on EPS for the fourth time running. Analysts expect 2026 adjusted EPS of ~$25.28 on ~$48.0 billion of revenue and ~$27.79 on ~$50.5 billion in 2027, roughly 10% growth each year, and the ~$757 mean target from 25 analysts sits about 12% above the November 20 price. Trailing free cash flow of ~$6.4 billion still gives the company flexibility for repurchases, dividends and acquisitions.
Headline figures (approximate, November 2026): RVTY shows revenue (ttm) ~$2.94 billion for the twelve months to October 4, 2026, with third-quarter revenue of ~$709.6 million up about 4.3% year over year and above the ~$695 million consensus. Growth has been slow rather than absent: ~$2.751 billion in fiscal 2023, ~$2.755 billion in fiscal 2024 and ~$2.856 billion in fiscal 2025. Analysts expect ~$2.87 billion for fiscal 2026 and ~$3.04 billion for 2027. Note that fiscal 2026 ends January 3, 2027 and contains 53 weeks, one more than fiscal 2025., gaap earnings versus adjusted earnings Trailing twelve-month net income is ~$253 million and trailing diluted EPS ~$2.25, against $2.07 for full-year 2025 and $2.20 for 2024. Adjusted EPS was $1.37 in the September quarter against a $1.30 estimate, after $1.41 against $1.22 in the June quarter and $1.06 against $1.01 in the March quarter. In the June quarter the bridge was $0.76 of intangible amortization, $0.32 of restructuring, $0.05 of investment mark-to-market and $0.02 of purchase accounting, less $0.21 of tax. Consensus adjusted EPS is ~$5.44 for 2026 and ~$5.96 for 2027; in August management had guided 2026 pro forma adjusted EPS to $5.30 to $5.40., margins On Yahoo Finance's trailing basis, gross margin is ~55.9%, GAAP operating margin ~16.7% and net margin ~8.6%. Adjusted operating margin ran 28.9% in the June quarter against a GAAP operating margin of 12.2%, the gap being intangible amortization from past acquisitions., segment and product-line mix First-half 2026 revenue splits almost evenly, Life Sciences ~$720.5 million and Diagnostics ~$720.3 million. Within Life Sciences: Life Sciences Solutions ~$601.0 million and Signals software ~$119.5 million. Within Diagnostics: immunodiagnostics ~$416.6 million and reproductive health ~$303.7 million. Segment adjusted operating margins in the June quarter were 31.1% for Life Sciences (down from 31.6%) and 30.4% for Diagnostics (up from 25.2%).; TMO shows revenue (ttm) ~$47.4 billion; full year 2025 ~$44.6 billion, q3 2026 revenue ~$12.14 billion, up ~9% year over year, q3 2026 adjusted eps ~$6.68 vs ~$6.40 expected, margins (ttm) Gross ~41%, GAAP operating ~19%, net ~15%.
The bottom line: RVTY vs TMO
RVTY and TMO are related but distinct: same themes, different businesses and risks. Neither wins in the abstract, and whichever you pick is worth sizing so one theme does not take over your portfolio. Walnut can show your combined RVTY and TMO exposure against your real portfolio. It is not an investment adviser.
Wondering how RVTY or TMO fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Your questions about Revvity
Ask Walnut's AI anything about RVTY and see how it fits what you own.
FAQ
What is the difference between RVTY and TMO?
+
Revvity runs two reporting segments of nearly identical size. Thermo Fisher Scientific, headquartered in Waltham, Massachusetts, is a global provider of scientific instruments, consumables, reagents, and services used across pharmaceutical and biotech drug development, clinical diagnostics, academic research, and environmental and industrial testing. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is RVTY or TMO the better stock?
+
Neither is universally better. TMO is the larger incumbent; RVTY is the smaller challenger and looks pricier on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, RVTY or TMO?
+
On forward P/E (as of November 2026), RVTY trades at 24.48x and TMO at 24.26x, so TMO is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both RVTY and TMO?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of RVTY vs TMO?
+
RVTY: The most immediate risk is that a chunk of 2026 profit does not repeat. Following the Supreme Court's February 20, 2026 ruling that the International Emergency Economic Powers Act does not authorize tariffs, Revvity applied through the Customs and Border Protection refund process for $20.2 million and had received $16.2 million by July 5, 2026. The company books these on receipt and has recorded no refund receivable, and the full $16.2 million landed in cost of revenue in a single quarter, worth roughly $0.11 of the $1.41 adjusted EPS and a good part of the 260 basis points of gross margin expansion. Second, the end market has not fully turned. Pharma and biotech sales declined mid-single digits including software in the quarter, academic and government budgets remain unsettled, and instruments are a deferrable purchase when customers are cautious. Third, the China divestiture is signed but not closed, with completion expected only by the end of 2027 and conditioned on regulatory approval, so Revvity carries the unit's declining results in the meantime while guiding without it. Fourth, the balance sheet is intangible-heavy: ~$6.61 billion of goodwill and ~$2.22 billion of net intangibles against ~$12.05 billion of total assets and ~$7.23 billion of equity, which leaves real impairment exposure if any acquired franchise underperforms. Fifth, restructuring is ongoing and disruptive, with severance actions in the first half of 2026 touching roughly 5% of the workforce and ~$46.2 million of charges recorded. Sixth, reproductive health revenue is tied to birth rates and to public-health screening budgets, both outside the company's control, and tuberculosis testing in the Americas is already a stated drag. Debt is ~$2.65 billion after the July repayment, with interest expense of ~$47.7 million in the half. Finally, after a roughly 48% gain in 2026 the stock trades near $145 and at about 24 times expected 2027 earnings, a premium to its own history that leaves little room for a guidance miss, and the shares already fell about 8.5% in the month to November 20 despite a third-quarter beat. Reported revenue growth was only about 4.3% in that quarter, so most of the earnings growth still has to come from margin and share count. TMO: The most significant near-term risk is a contraction in research funding from government agencies (including NIH) and from biotech companies whose access to capital markets has historically been cyclical; when funding tightens, customers delay instrument purchases and reduce consumable orders, pressuring organic revenue growth. Thermo Fisher's active acquisition strategy carries integration and leverage risk, particularly after committing approximately $13 billion to mergers and acquisitions in 2025 alone; total debt stood near ~$41.4 billion against ~$6.1 billion of cash on the September 2026 balance sheet, and a large deal that underperforms expectations could weigh on earnings and the balance sheet simultaneously. Geopolitical friction, particularly regarding China, creates both a demand risk (softer orders from Chinese academic and industrial customers) and a supply chain risk, while tariff policy changes can disrupt cost structures. Finally, valuation risk remains: the stock trades near ~36 times trailing GAAP earnings and ~24 times forward estimates, so a slip in growth from the third quarter's ~9% pace would test a multiple that has already expanded this year.
Related comparisons
Browse all stock comparisons.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell RVTY or TMO; figures are approximate and dated (as of November 2026). Verify current data before investing.